UNI-EN 134:Nofication for received approval from the FSC of the contract for transformation through merger of Unipharm AD in Sopharma AD
Firma: SOPHARMA ADSpis treści:
1. REPORT
2. INFORMATION ABOUT THE ENTITY
3. SIGNATURE OF PERSONS REPRESENTING THE COMPANY
Spis załączników:
| POLISH FINANCIAL SUPERVISION AUTHORITY | |||||||||||
|
| UNI - EN REPORT No | 134 | / | 2017 | |||||||
| Date of issue: | 2017-12-21 | ||||||||||
| Short name of the issuer | |||||||||||
| SOPHARMA AD | |||||||||||
| Subject | |||||||||||
| Nofication for received approval from the FSC of the contract for transformation through merger of Unipharm AD in Sopharma AD | |||||||||||
| Official market - legal basis | |||||||||||
| art. 56. 1. 2 of Act on Public Offering. | |||||||||||
| Unofficial market - legal basis | |||||||||||
| Contents of the report: | |||||||||||
| Sopharma AD notifies that on 20 December 2018 Sopharma AD received an approval from the FSC of the contract for transformation through merger of Unipharm AD in Sopharma AD and reports of the boards of directors and the independent evaluators. The fair price of the participants in the transformation is based on widely accepted evaluation methods. Based on the fair price the participants in the transformation reached a ratio of exchange of 0. 891512, meaning that one share of Unipharm AD will be exchanged for 0. 891512 shares of Sopharma AD from the treasury shares available to the receiving company. The terms and conditions of the merger are available in detail in the Contract for transformation through merger and the reports of the boards of directors and the independent evaluators which are subject to approval by the general meetings of shareholders of both companies. The procedures for convening general meetings for both companies will be initiated in the beginning of 2018. | |||||||||||
| Annexes | |||||||||||
| File | Description | ||||||||||
| Notification-merger-21-12.doc Notification-merger-21-12.doc | Nofication for received approval from the FSC of the contract for transformation through merger of Unipharm AD in Sopharma AD | ||||||||||
| SOPHARMA AD | |||||||||||||
| (fullname of the issuer) | |||||||||||||
| SOPHARMA AD | Farmaceutyczny (far) | ||||||||||||
| (short name of the issuer) | (sector according to clasification of the WSE in Warsow) | ||||||||||||
| 1220 | Sofia | ||||||||||||
| (post code) | (city) | ||||||||||||
| IlienskoShosse | 16 | ||||||||||||
| (street) | (number) | ||||||||||||
| +359 2 813 42 00 | +359 2 936 02 86 | ||||||||||||
| (phone number) | (fax) | ||||||||||||
| (e-mail) | (web site) | ||||||||||||
| nd | |||||||||||||
| (NIP) | (REGON) | ||||||||||||
| SIGNATURE OF PERSONS REPRESENTING THE COMPANY | |||||
| Date | Name | Position / Function | Signature | ||
| 2017-12-21 | Ognian Donev | Executive Director | |||
Cena akcji Sopharma
Cena akcji Sopharma w momencie publikacji komunikatu to 9.7 PLN. Sprawdź ile kosztuje akcja Sopharma aktualnie.
W tej sekcji znajdziesz wszystkie komunikaty ESPI EBI Sopharma.
